中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 3
Mar.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(3): 506-512

Influencing factors for meropenem-related liver injury and their predictive value

DOI: 10.12449/JCH250317
  • 1.

    Department of Pharmacy of Renmin Hospital，Hubei Key Laboratory of Wudang Local Chinese Medicine Research，Hubei University of Medicine，Shiyan，Hubei 442000，China

  • 2.

    School of Pharmaceutical Sciences，Hubei University of Medicine，Shiyan，Hubei 442000，China

  • 3.

    Department of Pharmacy，Taihe Hospital，Hubei University of Medicine，Shiyan，Hubei 442000，China

  • 4.

    Department of Respiratory Medicine，Renmin Hospital，Hubei University of Medicine，Shiyan，Hubei 442000，China

Research funding:

Natural Science Foundation of Hubei Provincial (2023AFB925);

the Advantages Discipline Group （Biology and Medicine） Project in Higher Education of Hubei Province （2021-2025） (2023BMXKQT5);

the Open Project of Hubei Key Laboratory of Wudang Local Chinese Medicine Research （Hubei University of Medicine） (WDCM2023013)

More Information
  • Corresponding author: YU Huibin， qingyun125@163.com （ORCID： 0009-0009-0901-5632）
  • Received Date: 2024-08-05
  • Accepted Date: 2024-10-10
  • Published Date: 2025-03-25
    Abstract
  •   Objective  To analyze the factors influencing meropenem-related liver injury （MRLI） and to explore their clinical predictive value.  Methods  A retrospective case-control study was conducted， and the Chinese Hospital Pharmacovigilance System （CHPS） was used to establish a retrieval scheme. A total of 1 625 hospitalized cases using meropenem from January 2018 to December 2022 were collected. Patients were divided into case group （n=62） and control group （n=1 563） based on the presence or absence of liver injury. Clinical data and laboratory indicators from both groups were collected and analyzed. The t-test was used for comparison of normally distributed continuous data between the two groups， while the Mann-Whitney U test was used for comparison of continuous data not conforming to a normal distribution. The chi-square test was used for comparison of categorical data between the two groups. A multivariate Logistic regression analysis was performed to identify the influencing factors for MRLI. A Logistic regression equation was established， and the predictive value of these factors was assessed using the receiver operating characteristic （ROC） curve.  Results  The results of univariate analysis indicated that the rates of male patients， hypoproteinemia， shock， intensive care unit （ICU） admissions， sepsis， and liver， gallbladder， and cardiovascular diseases， the levels of alanine aminotransferase （ALT）， alkaline phosphatase （ALP）， gamma-glutamyl transpeptidase （GGT）， aspartate aminotransferase （AST）， creatinine （CREA）， and procalcitonin （PCT）， and the number of hospitalization days were significantly higher in the case group than in the control group （P<0.05）， and that the platelet levels in the case group were significantly lower than those in the control group （P<0.05）. The multivariate Logistic regression analysis showed that male sex （odds ratio ［OR］=2.080， 95% confidence interval ［CI］： 1.050 — 4.123， P=0.036）， admission to the ICU （OR=8.207， 95%CI： 4.094‍ ‍—‍ ‍16.453， P<0.001）， comorbidity with gallbladder disease （OR=8.240， 95%CI： 3.605‍ ‍—‍ ‍18.832， P<0.001）， ALP （OR=1.012， 95%CI： 1.004‍ ‍—‍ ‍1.019， P=0.004）， GGT （OR=1.010， 95%CI： 1.005‍ ‍—‍ ‍1.015， P<0.001）， and PLT （OR=0.997， 95%CI： 0.994‍ ‍—‍ ‍0.999， P=0.020） were the influential factors for MRLI. The areas under the ROC curve of ALP， GGT， and PLT were 0.589， 0.637， and 0.595， respectively， and the AUC of them combined was 0.837.  Conclusion  Male sex， ICU admission， comorbidity with gallbladder disease， increased ALP， increased GGT， and decreased PLT were influencing factors for MRLI， and a combination of factors has a better predictive value for the occurrence of MRLI.

     

    • FullText(HTML)
    • References(36)
  • [1]
    GOBEZIE MY, HASSEN M, TESFAYE NA, et al. Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta-analysis[J]. Antimicrob Resist Infect Control, 2024, 13( 1): 37. DOI: 10.1186/S13756-024-01389-2.
    [2]
    XING G, LIU XL, HUANG JH. Meropenem induced cholestatic liver injury: a case report[J]. Herald of Med, 2018, 37( 7): 913- 914. DOI: 10.3870/j.issn.1004-0781.2018.07.033.

    邢刚, 刘晓玲, 黄建华. 美罗培南致胆汁淤积性肝损伤1例[J]. 医药导报, 2018, 37( 7): 913- 914. DOI: 10.3870/j.issn.1004-0781.2018.07.033.
    [3]
    WEBER S, GERBES AL. Challenges and future of drug-induced liver injury research-laboratory tests[J]. Int J Mol Sci, 2022, 23( 11): 6049. DOI: 10.3390/ijms23116049.
    [4]
    Technical Committee of Prevention and Treatment of Drug-induced Liver Injury, Chinese Medical Biotechnology Association, Drug Hepatology Group, Branch Hepatology, Chinese Medical Association. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
    [5]
    HAN J, LIU J, YU Z, et al. Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China[J]. BMJ Open, 2023, 13( 6): e069794. DOI: 10.1136/bmjopen-2022-069794.
    [6]
    HAYASHI PH, LUCENA MI, FONTANA RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI[J]. Hepatology, 2022, 76( 1): 18- 31. DOI: 10.1002/hep.32327.
    [7]
    WANG SM, JIN S, LI JR, et al. Influencing factors for the prognosis of patients with drug-induced liver injury and establishment of a nomogram model[J]. J Clin Hepatol, 2024, 40( 3): 562- 567. DOI: 10.12449/JCH240320.

    王诗美, 靳帅, 李俊儒, 等. 药物性肝损伤患者预后影响因素分析及列线图模型的建立[J]. 临床肝胆病杂志, 2024, 40( 3): 562- 567. DOI: 10.12449/JCH240320.
    [8]
    LIN LM, HONG MH, WU DN, et al. Incidence and risk factors of voriconazole-induced liver injury in the context of therapeutic drug monitoring[J]. Chin J Infect Chemotherapy, 2023, 23( 6): 709- 714. DOI: 10.16718/j.1009-7708.2023.06.007.

    林良沫, 洪绵慧, 吴丹娜, 等. 血药浓度监测与伏立康唑致肝损伤的发生情况及影响因素分析[J]. 中国感染与化疗杂志, 2023, 23( 6): 709- 714. DOI: 10.16718/j.1009-7708.2023.06.007.
    [9]
    YANG XM, SHEN BR, LIU PY, et al. Logistic regression analysis of risk factors of antituberculosis drug-induced liver injury[J]. Chin J Hosp Pharm, 2019 39( 1): 67- 71. DOI: 10.13286/j.cnki.Chinhosppharmacyj.2019.01.15.

    杨学敏, 沈宝荣, 刘鹏园, 等. 抗结核药致药物性肝损伤危险因素的Logistic回归分析[J]. 中国医院药学杂志, 2019, 39( 1): 67- 71. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.01.15.
    [10]
    ZHONG T, FAN YZ, DONG XL, et al. An Investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis[J]. Front Pharmacol, 2021, 12: 708522. DOI: 10.3389/fphar.2021.708522.
    [11]
    LIN YX, LI PP, ZHANG YP, et al. Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study[J]. Hepatol Int, 2024, 18( 6): 1756- 1769. DOI: 10.1007/s12072-023-10627-5.
    [12]
    YU ZW, ZHAO YH, JIN JY, et al. Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study[J]. Int J Infect Dis, 2022, 120: 59- 64. DOI: 10.1016/j.ijid.2022.04.024.
    [13]
    LIU XZ, LIU JJ, FANG X, et al. A real-world study of azivudine tablets for drug-induced liver injury caused by novel coronavirus pneumonia[J]. Chin J Hosp Pharm, 2024, 44( 9): 1082- 1087. DOI: 10.13286/j.1001-5213.2024.09.12.

    刘秀珍, 刘建军, 方兴, 等. 阿兹夫定片治疗新型冠状病毒肺炎引起药物性肝损伤真实世界研究[J]. 中国医院药学杂志, 2024, 44( 9): 1082- 1087. DOI: 10.13286/j.1001-5213.2024.09.12.
    [14]
    EDER P, PERMODA-OSIP A, MAJEWSKI P, et al. Agomelatine-induced liver injury in a patient with choledocholithiasis[J]. Acta Neuropsychiatr, 2014, 27( 1): 56- 59. DOI: 10.1017/neu.2014.28.
    [15]
    WEI Q, LI L, ZENG XQ, et al. Analysis of clinical features and prognostic risk factors in patients with drug-induced liver injury[J]. Chin J Hepatol, 2024, 32( 3): 214- 221. DOI: 10.3760/cma.j. cn501113-20240201-00072.

    魏倩, 李蕾, 曾晓清, 等. 药物性肝损伤患者的临床特征及预后相关危险因素分析[J]. 中华肝脏病杂志, 2024, 32( 3): 214- 221. DOI: 10.3760/cma.j.cn501113-20240201-00072.
    [16]
    PAPP-WALLACE KM, ENDIMIANI A, TARACILA MA, et al. Carbapenems: Past, present, and future[J]. Antimicrob Agents Chemother, 2011, 55( 11): 4943- 4960. DOI: 10.1128/AAC.00296-11.
    [17]
    DENG XY, HUANG JJ, SUN J, et al. Incidence and risk factors of drug-induced liver injury in patients with novel coronavirus pneumonia[J]. ADRJ, 2020, 22( 6): 360- 365. DOI: 10.3760/cma.j.cn114015-20200331-00322.

    邓轩宇, 黄娟娟, 孙吉, 等. 新型冠状病毒肺炎患者药物性肝损伤发生情况及其危险因素分析[J]. 药物不良反应杂志, 2020, 22( 6): 360- 365. DOI: 10.3760/cma.j.cn114015-20200331-00322.
    [18]
    TATTERSALL T, WRIGHT H, REDMOND A. Meropenem-induced liver injury and beta-lactam cross-reactivity[J]. BMJ Case Rep, 2018, 11( 1): e227124. DOI: 10.1136/bcr-2018-227124.
    [19]
    CHEUNG S, BULOVIC J, PILLAI A, et al. A case of meropenem-induced liver injury and jaundice[J]. J Community Hosp Intern Med Perspect, 2021, 11( 1): 143- 144. DOI: 10.1080/20009666.2020.1845929.
    [20]
    YANG JQ, ZHAO WX, ZHOU C, et al. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. J Clin Hepatol, 2024, 40( 8): 1579- 1584. DOI: 10.12449/JCH240812.

    杨金秋, 赵文霞, 周铖, 等. 非酒精性脂肪性肝病发生进展期肝纤维化的危险因素及列线图预测模型构建[J]. 临床肝胆病杂志, 2024, 40( 8): 1579- 1584. DOI: 10.12449/JCH240812.
    [21]
    WU XJ, PENG JL, FAN H, et al. Clinical features and prognostic factors of 310 patients with antituberculosis drug-induced liver injury[J]. J Kunming Med Univ, 2024, 45( 3): 157- 165. DOI: 10.12259/j.issn.2095-610X. S20240324.

    吴雪娇, 彭江丽, 樊浩, 等. 310例抗结核药物性肝损伤患者临床特点及预后影响因素分析[J]. 昆明医科大学学报, 2024, 45( 3): 157- 165. DOI: 10.12259/j.issn.2095-610X.S20240324.
    [22]
    LV BB, LIU LS, LIU XM, et al. Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study[J]. Front Pharmacol, 2023, 14: 1126765. DOI: 10.3389/fphar.2023.1126765.
    [23]
    ZHU YH, WANG XS, SONG MF, et al. Characteristies of acute liver injury in elderly patients with sepsis in intensive care unit and its influencing factors[J]. Chin J Mult Organ Dis Elderly, 2023, 22( 5): 362- 366. DOI: 10.11915/j.issn.1671-5403.2023.05.74.

    朱玉菡, 王旭升, 宋麦芬, 等. 重症监护室老年脓毒症患者合并急性肝损伤的特征及影响因素[J]. 中华老年多器官疾病杂志, 2023, 22( 5): 362- 366. DOI: 10.11915/j.issn.1671-5403.2023.05.74.
    [24]
    HE Y, LI BL, LI H. Analysis of influencing factors on drug-induced liver injury induced by antituberculosis therapy in patients with newly treated pulmonary tuberculosis combined with hepatitis B virus infection[J]. J Changchun Univ Chin Med, 2024, 40( 4): 450- 454. DOI: 10.13463/j.cnki.cczyy.2024.04.023.

    贺毅, 李榜龙, 李慧. 初治肺结核合并乙型肝炎病毒感染患者抗结核治疗诱发药物性肝损伤的影响因素分析[J]. 长春中医药大学学报, 2024, 40( 4): 450- 454. DOI: 10.13463/j.cnki.cczyy.2024.04.023.
    [25]
    WANG JF, ZHAO L, WANG JJ, et al. The study of serum TBA, ALP and coagulation function in sepsis patients with liver injury[J]. Chin Hepatol, 2022, 27( 5): 593- 595. DOI: 10.14000/j.cnki.issn.1008-1704.2022.05.024.

    王俊峰, 赵亮, 王俊杰, 等. 脓毒血症肝损伤患者血清TBA、ALP水平与凝血功能特征观察[J]. 肝脏, 2022, 27( 5): 593- 595. DOI: 10.14000/j. cnki.issn.1008-1704.2022.05.024.
    [26]
    DAI XY, ZHENG YY, TANG JN, et al. Alkaline phosphatase-to-albumin ratio as a novel predictor of long-term adverse outcomes in coronary artery disease patients who underwent PCI[J]. Biosci Rep, 2021, 41( 7): BSR20203904. DOI: 10.1042/BSR20203904.
    [27]
    VILLANUEVAPAZ M, MORAN L, LOPEZALCANTARA N, et al. Oxidative stress in drug-induced liver injury(DILI): From mechanisms to biomarkers for use in clinical practice[J]. Antioxidants(Basel), 2021, 10( 3): 390. DOI: 10.3390/antiox10030390.
    [28]
    JIANG YY, SHI L, LIU Y. Correlation between gamma-glutamyl transferase and coronary heart disease[J]. Chin Gen Pract, 2021, 24( 2): 176- 182. DOI: 10.12114/j.issn.1007-9572.2020.00.422.

    蒋元英, 史玲, 刘瑶. γ-谷氨酰转移酶与冠心病的相关性研究[J]. 中国全科医学, 2021, 24( 2): 176- 182. DOI: 10.12114/j.issn.1007-9572.2020.00.422.
    [29]
    DENG Y, WANG CY, TAN WH, et al. High risk factors associated with relapse of chronic drug-induced liver injury[J]. Med J Chine PLA, 2021, 46( 9): 928- 934. DOI 10.11855/j.issn.0577-7402.2021.09.14. DOI: 10.11855/j.issn.0577-7402.2021.09.14

    邓亚, 王春艳, 谭文辉, 等. 慢性药物性肝损伤复发的高危因素分析[J]. 解放军医学杂志, 2021, 46( 9): 928- 934. DOI: 10.11855/j.issn.0577-7402.2021.09.14.
    [30]
    ZHANG ZJ, LIU Y. Analysis of influencing factors of acute liver failure in 147 patients with liver injury induced by antituberculosis drugs[J]. Chin Hepatol, 2024, 29( 5): 552- 556. DOI: 10.3969/j.issn.1008-1704.2024.05.017.

    张昭君, 刘跃. 抗结核药物性肝损伤患者急性肝功能衰竭的影响因素分析[J]. 肝脏, 2024, 29( 5): 552- 556. DOI: 10.3969/j.issn.1008-1704.2024.05.017.
    [31]
    WANG QL, LIANG QS, HUANG A, et al. Influencing factors for the prognosis of biopsy proven patients with chronic drug-induced liver injury: An analysis of 255 cases[J]. J Clin Hepatol, 2022, 38( 6): 1334- 1340. DOI: 10.3969/j.issn.1001-5256.2022.06.022.

    王巧玲, 梁庆生, 黄昂, 等. 255例肝穿刺证实的慢性药物性肝损伤患者预后的影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 6): 1334- 1340. DOI: 10.3969/j.issn.1001-5256.2022.06.022.
    [32]
    GENG JL, ZHANG YN, PAN HQ. Establishment and validation of a risk prediction model for drug-induced liver injury in patients with tuberculosis[J]. Chin J Antituberc, 2024, 46( 6): 699- 706. DOI: 10.19982/j.issn.1000-6621.20240030.

    耿俊玲, 张伊楠, 潘洪秋. 结核病患者发生药物性肝损伤风险预测模型的构建与验证[J]. 中国防痨杂志, 2024, 46( 6): 699- 706. DOI: 10.19982/j.issn.1000-6621.20240030.
    [33]
    Committee of Neoplastic Supportive-care(CONS), China Anti Cancer Association. Chinese expert consensus on management of thrombocytopenia in cancer patients with liver injury(2022 edition)[J]. J Clin Hepatol, 2023, 39( 6): 1287- 1294. DOI: 10.3971/j.issn.1000-8578.2023.23.0156.

    中国抗癌协会肿瘤支持治疗专业委员会.. 肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版)[J]. 临床肝胆病杂志, 2023, 39( 6): 1287- 1294. DOI: 10.3971/j.issn.1000-8578.2023. 23.0156.
    [34]
    CHRISTOPHE L, JEAN-LOUIS V. Mechanisms and treatment of organ failure in sepsis[J]. Nat Rev Nephrol, 2018, 14( 7): 417- 427. DOI: 10.1038/s41581-018- 0005-7.
    [35]
    JIANG F, YAN H, LIANG L, et al. Incidence and risk factors of anti‐tuberculosis drug induced liver injury(DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients[J]. Liver Int, 2021, 41( 7): 1565- 1575. DOI: 10.1111/liv.14896.
    [36]
    LI XY, TANG JT, MAO YM. Incidence and risk factors of drug‐induced liver injury[J]. Liver Int, 2022, 42( 9): 1999- 2014. DOI: 10.1111/liv.15262.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (62) PDF downloads(10) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1878]YesterdayPV[3517]TodayIP[162]TodayPV[235]Online[13]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return